Get started
Author

Harald Schmalenberg

Observed names: H Schmalenberg, H. Schmalenberg, H., Schmalenberg, Schmalenberg, H., Schmalenberg, Harald
Observed institutions: Universität Hamburg, Friedrich-Alexander-Universität Erlangen-Nürnberg, Johannes Gutenberg University Mainz, Städtisches Klinikum Dresden, University Hospital Münster, Klinikum Oldenburg, Allgemeines Krankenhaus Celle, Krankenhaus Dresden-Friedrichstadt, University Hospital Leipzig, Krankenhaus Nordwest, Jena University Hospital, University Hospital Magdeburg, University Hospital Ulm, University Medical Centre Mannheim, University Hospital Carl Gustav Carus, Klinikum Chemnitz, Stiftung Charité, Martin Luther University Halle-Wittenberg, Friedrich Schiller University Jena, Charité – Universitätsmedizin Berlin, University of Tübingen, Otto-von-Guericke-Universität Magdeburg
OpenAlex ID: A5066426980
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
2019 · Salah-Eddin Al-Batran, Nils Homann, et al. · The Lancet · 2,744
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 · Helmut Oettle, Stefan Post, et al. · JAMA · 2,447
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
2008 · Salah-Eddin Al-Batran, Joerg Thomas Hartmann, et al. · Journal of Clinical Oncology · 784
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
2016 · Salah-Eddin Al-Batran, Ralf D Hofheinz, et al. · The Lancet Oncology · 765
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer
2017 · Salah-Eddin Al-Batran, Nils Homann, et al. · JAMA Oncology · 489
PDF
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
2017 · Salah-Eddin Al-Batran, Thorsten O. Goetze, et al. · BMC Cancer · 243
PDF
Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.
2017 · Salah-Eddin Al-Batran, Nils Homann, et al. · Journal of Clinical Oncology · 240
Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma
2002 · Ulrich Kaiser, Irmgard Uebelacker, et al. · Journal of Clinical Oncology · 138
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
2013 · S Lorenzen, C Pauligk, et al. · British Journal of Cancer · 115
PDF
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the GermanHigh-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)
2003 · A. Wunderlich, M. Kloess, et al. · Annals of Oncology · 98
Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer
2015 · Johanna Inhestern, Katrin Oertel, et al. · PLoS ONE · 73
PDF
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
2009 · A D Wagner, P Buechner-Steudel, et al. · British Journal of Cancer · 57
PDF
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
2017 · J. Inhestern, H. Schmalenberg, et al. · Annals of Oncology · 46
PDF
Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
2017 · S-E. Al-Batran, C. Pauligk, et al. · Annals of Oncology · 43
Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
2016 · Olaf Schoffer, Stefanie Schülein, et al. · BMC Cancer · 36
PDF
Incidence, treatment, and outcome of parotid carcinoma, 1996–2011: a population-based study in Thuringia, Germany
2015 · Orlando Guntinas-Lichius, Thomas G. Wendt, et al. · Journal of Cancer Research and Clinical Oncology · 35
Trends in epidemiology and treatment and outcome for head and neck cancer: A population-based long-term analysis from 1996 to 2011 of the Thuringian cancer registry
2014 · Orlando Guntinas-Lichius, Thomas G. Wendt, et al. · Oral Oncology · 34
A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)
2006 · S. Al-Batran, J. T. Hartmann, et al. · Journal of Clinical Oncology · 33
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
2020 · Salah-Eddin Al-Batran, Ralf Dieter Hofheinz, et al. · Journal of Clinical Oncology · 29
Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)
2017 · Salah-Eddin Al-Batran, Claudia Pauligk, et al. · Annals of Oncology · 29
The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer
2011 · S.-E. Al-Batran, C. Pauligk, et al. · Annals of Oncology · 29
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
2023 · Thorsten O. Goetze, Ralf‐Dieter Hofheinz, et al. · International Journal of Cancer · 26
Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial
2017 · T Götze, N Homann, et al. · Zeitschrift für Gastroenterologie · 26
Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene
2008 · A. B. P. van Kuilenburg, J. G. Maring, et al. · Nucleosides Nucleotides & Nucleic Acids · 26
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
2019 · Salah-Eddin Al-Batran, Claudia Pauligk, et al. · Journal of Clinical Oncology · 23
Works count: 94
Citation count: 8,805
H-index: 24
I10-index: 32
Year
Topic
Type